Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2a trial of inhaled BX004-A bacteriophage therapy in adults with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection
MOH_2022-01-06_010530Phase 2Active, not recruiting
- Sponsor
- BiomX
- Start
- Jan 2022
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) and Pseudomonas aeruginosa pulmonary infection comparing BX004-A with Placebo (2 arms). Primary endpoint: Safety and tolerability of inhaled BX004-A. Started Jan 2022; status: active, not recruiting.
02
Drugs
BX004
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on MOH_2022-01-06_010530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-06_010530.